M. Madin-Warburton

Cost-Effectiveness Analysis Of Regorafenib In Gastrointestinal Stromal Tumours In England Using Crossover Adjustment Methods

A. Pitcher, E. Grabbi, M. Madin-Warburton, 2016 .

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England

A. Pickard, K. Chaudhuri, A. Schrag, 2022, PharmacoEconomics.

Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application

F. Meheus, M. Madin-Warburton, A. Solomon, 2016, PLoS neglected tropical diseases.

Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany

D. Tamoschus, A. Pitcher, M. Madin-Warburton, 2017, Clinical Drug Investigation.

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI

M. Madin-Warburton, Elaine Finn, F. Andersson, 2021, BMC Infectious Diseases.

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

H. Ishii, Shuichi Suzuki, M. Madin-Warburton, 2018, Journal of medical economics.

Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model

M. Madin-Warburton, M. van Keep, Renu B. Patel, 2023, Frontiers in Medical Technology.

Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.

M. Amonkar, Jan Mikelson, M. Madin-Warburton, 2024, Journal of medical economics.